medigraphic.com
Colegio de Medicina Interna de México.

2017, Number 6

<< Back Next >>

Med Int Mex 2017; 33 (6)

Early death risk stratification in post-myocardial infarction patients based on plasma copeptin levels

Godínez-Baca LE, Luna-Pérez D

Language: Spanish
References: 22
Page: 754-763
PDF size: 569.32 Kb.


ABSTRACT

Background: Copeptin is a novel biomarker that has demonstrated good diagnostic performance in the early diagnosis of patients with acute coronary syndrome; however, its prognostic performance in the short-term survival (28 days) has not been established.
Objective: To determine the prognostic performance of copeptin for 28 day-mortality in patients with acute coronary syndrome.
Material and Method: A prospective, observational cohort of patients with acute coronary syndrome was done from January 1st 2014 to November 30 2015, measuring copeptin at presentation, registering deaths and event-free survivors over 28 days.
Results: Thirty-four patients were included, stratified as having low risk of death if copeptin was ≤ 12 pmol/L, intermediate risk between 12.1 and 32.5 pmol/L, and high risk ≥ 32.5 pmol/L, with a mortality of 0%, 15% and 30%, respectively; hazard ratio between high and low adjusted to confuse factors of 15.9 (CI95% 1.3-190; p = 0.02, Cox multivariable regression model).
Conclusion: Elevated concentrations of copeptin are directly proportional to a higher risk of all-cause mortality, hence it could be used as a prognostic marker.


REFERENCES

  1. Martínez Ríos MA. Infarto agudo de miocardio: documento de Postura. Academia Nacional de Medicina. Ciudad de México: Intersistemas, 2014;130.

  2. Huerta Robles B. Epidemiología de los síndromes coronarios agudos. Arch Cardiol Mex 2007;77:S4 214-18.

  3. Von Haehling S, Papassotiriou J, Morgenthaler NG, y col. Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. Int J Cardiol 2012;162:27-32.

  4. Maisel A, Mueller C, Neath SX, y col. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial. J Am Coll Cardiol 2013;62:150-60.

  5. Wildi K, Zellweger C, Twerenbold R, y col. Incremental value of copeptin to highly sensitive cardiac troponin I for rapid rule out of myocardial infarction. Int J Cardiol 2015;190:170-76.

  6. Xue Y, Shah K, Maisel A, y col. Increased 90 day mortality in patients with elevated copeptin: secondary results from the biomarkers in acute heart failure (BACH) study. J Am Coll Cardiol 2010;55:10A.

  7. Kelly D, Squire I, Khan SQ, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling and clinical heart failure in survivors of myocardial infarction. J Cardiac Fail 2008;14:739-45.

  8. Voors A, Von Haehling S, Anker S, et al. C- terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009;30:1187-94.

  9. Yalta K, Yalta T, Sivri N, et al. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013 Sep 1;167(5):1750-9.

  10. Reinstadler S, Klug G, Feistritzer HJ, et al. Copeptin testing in acute myocardial infarction: ready for routine use? Dis Markers 2014:1-8.

  11. Katan M, Muller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Critical Care 2008;12:117.

  12. Marston N, Maisel A. The prognostic value of copeptin in patients with acute chest pain. Expert Rev Cardiovasc 2014;12(10):1237-42.

  13. Thelin J, Borna C, Erlinge D, et al. The combination of high sensitivity troponin T and copeptin facilitates early rule out of ACS: a prospective observational study. BMC Cardiovasc Disord 2013;13:1-8.

  14. Slagman A, Searle J, Muller C, et al. Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction. Clin Chem 2015; 61:1273-82.

  15. Vafaie M, Biener M, Mueller M, et al. Addition of copeptin improves diagnostic performance of point of care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction- A pilot study. Int J Cardiol 2015;26-30.

  16. Khan S, Dhillon O, O’Brien R, y col. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction peptide (LAMP) study. Circulation 2007; Apr 24;115(16):2103-10.

  17. Balmelli C, Meune C, Twerenbold R, y col. Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men. Am Heart J 2013;166:30-37.

  18. Zellweger C, Wildi K, Twerenbold R, et al. Use of copeptin and high sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction. Int J Cardiol 2015;190:190-97.

  19. Hillinger P, Twerenbold R, Jaeger C, et al. Optimizing early rule-out strategies for acute myocardial infarction: utility of 1 hour copeptin. Clin Chem 2015;61:1-8.

  20. Marston N, Shah K, Mueller C. Serial sampling of copeptin levels improves diagnois and risk stratification in patients presenting with chest pain: results from the CHOPIN trial. Emerg Med J 2016 Jan;33(1):23-9.

  21. Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140:1-6.

  22. Alehagen U, Dehlstrom U, Rehfeld J, et al. Association of copeptin and N-terminal pro-BNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 2011;305(20):2088-95.




2020     |     www.medigraphic.com